Study of B2065 for recent ischemic stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests an investigational drug called B2065 for people who have had a recent ischemic stroke (a stroke caused by a blockage in a blood vessel in the brain). The goal is to see if it is safe and if it might help improve recovery when given within 36 hours of stroke symptoms starting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had an ischemic stroke confirmed by a CT or MRI scan.
- You can receive the study drug within 36 hours of your stroke symptoms starting (or from the last time you were seen without symptoms if you woke up with the stroke).
- Your stroke symptoms are moderate to moderately severe (NIHSS score between 8 and 20).
- You have not already received clot-dissolving medicine or a mechanical clot removal procedure for this stroke.
- You do not have certain other serious medical conditions like uncontrolled high blood pressure, active infection, or severe organ disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.
This trial tests a new drug, HRS-4029, given within 3 hours of an ischemic stroke (a stroke caused by a blocked blood vessel). The goal is to see if the drug helps improve recovery.
This study tests an experimental drug called BB-031 to see if it can safely help people who have had a recent ischemic stroke (a clot that blocks blood flow to the brain). The trial is for people who can get to the hospital within 24 hours of their first symptoms and have a moderate to severe stroke.
This trial tests if TAK-755 can help people who have had a moderate to severe stroke within the last 24 hours. It aims to see if the drug can improve recovery by protecting brain tissue that is still salvageable.
This Phase 2 trial studies whether adding TBO-309 to standard emergency treatment for acute ischemic stroke is safe and tolerable. It may help researchers see if the added drug can be given without causing excessive side effects alongside clot-busting and/or clot-removal procedures.
This study tests whether a new drug called QD202 can help protect the brain and improve recovery when given alongside standard clot-busting therapy (thrombolysis) for acute ischemic stroke. You would be in the trial if you had a stroke in the last 24 hours and are receiving or planning to receive thrombolytic treatment.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.